Inovio Says Preclinical Data Suggest Potential of COVID-19 Vaccine Candidate Against Different Viral Variants
08:35 AM EDT, 05/12/2021 (MT Newswires) -- Inovio Pharmaceuticals (INO) said Wednesday its COVID-19 vaccine candidate may have potential to induce immune responses against different variants of the SARS-CoV-2 virus, based on data from its preclinical study.
In the study, the vaccine induced potent neutralizing antibodies and T-cell responses against the original strain, as well as the UK, South African, and Brazilian variants of the virus.
The company is now planning to conduct phase 1/2 clinical trials this year, according to the statement.
Shares in the drug maker were up more than 4% in recent premarket activity Wednesday.
Price: 6.77, Change: +0.28, Percent Change: +4.31